Swedish Orphan Biovitrum AB (publ) banner

Economic Moat

Swedish Orphan Biovitrum has a narrow economic moat

Patents and temporary market protections on some of Sobi’s rare-disease medicines delay direct copies, helping it retain sales while rivals develop and test alternatives. Other medicines can still treat the same conditions, so these protections provide a limited barrier rather than keeping all competitors out.

What protects Swedish Orphan Biovitrum from competitors

Intangible Assets

Patents and market-exclusivity rights on selected Sobi medicines make it harder for rivals to sell direct copies in the rare-disease markets those treatments serve. This can protect sales while the rights remain in force, although competing treatments may still be available.

What could weaken Swedish Orphan Biovitrum's moat

1 risk to watch

What could happen to the source of the moat and how it would weaken it